ArticleTranslational cancer research2025
LINC02081 as an oncogene promotes cell proliferation and G2/M cycle through p53 signaling pathway in lung adenocarcinoma.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: LINC02081 is a newly identified long non-coding RNA (lncRNA) with an uncharacterized biological function. This study aimed to investigate the role of LINC02081 in lung adenocarcinoma (LUAD). Methods: Bioinformatics analysis utilizing The Cancer Genome Atlas (TCGA) database assessed LINC02081 expression and its clinical significance. Nuclear and cytoplasmic RNA fractionation detected the subcellular localization of LINC02081. Cell proliferation was evaluated using Cell Counting Kit-8 (CCK-8) assays, 5-ethynyl-2'-deoxyuridine (EdU) assays, and colony formation assays. Flow cytometry analyzed the cell cycle and apoptosis. p53 expression was assessed via immunofluorescence, while p21 messenger RNA (mRNA) levels were analyzed by reverse transcription quantitative polymerase chain reaction (RT-qPCR). Results: LINC02081 was highly expressed in LUAD tissues, both in the TCGA dataset and our clinical samples. Elevated LINC02081 expression correlated positively with poor prognosis and advanced clinical stage. LINC02081 localized predominantly to the nucleus. Gene enrichment analysis revealed significant associations between LINC02081 and both the cell cycle and p53 signaling pathway. Successful knockdown of LINC02081 using antisense oligonucleotides (ASOs) significantly suppressed LUAD cell proliferation, inhibited G2/M phase progression, and promoted cell apoptosis. Knockdown of LINC02081 promoted p53 and p21 expression. Conclusions: Our findings suggest that LINC02081 promotes the malignant progression of LUAD. This effect may involve the p53 signaling pathway. This study provides novel insights into LUAD pathogenesis and indicates LINC02081 may be a potential therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.